PLC Systems Receives FDA Approval To Commence Pivotal Study Of RenalGuard(TM) In The U.S. (Medical News Today)
PLC Systems Inc. (Amex: PLC) announced that it has received conditional approval from the U.S. Food and Drug Administration (FDA) to begin enrollment in a U.S. pivotal trial to study the effectiveness of the Company's RenalGuard Therapy(TM) and RenalGuard System(TM) in the prevention of Contrast-Induced Nephropathy (CIN). Mark R.

FDA Issues Approvable Letter For Ceftobiprole For Treatment Of Complicated Skin Infections (Medical News Today)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), announced that it received an approvable letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ceftobiprole for the treatment of complicated skin and skin structure infections, including diabetic foot infections.

PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S. (PR Newswire via Yahoo! Finance)
PLC Systems Inc. announced today that it has received conditional approval from the U.S. Food and Drug Administration to begin enrollment in a U.S. pivotal trial to study the effectiveness of the Company's RenalGuard Therapy and RenalGuard System in the prevention of Contrast-Induced Nephropathy .